Recurrent VTE events during the 60-day study period according to initial anticoagulation strategy
| VTE characteristics . | Full-dose (n = 75) . | Modified-dose (n = 33) . | None (n = 13) . |
|---|---|---|---|
| Total recurrent VTE events | 4 (5) | 0 | 1 (8) |
| Recurrent VTE event | |||
| Distal lower extremity DVT | 1 (1) | 0 | 0 |
| Proximal lower extremity DVT | 2 (3) | 0 | 0 |
| Upper extremity DVT | 0 | 0 | 1 (8) |
| Pulmonary embolism | 1 (1) | 0 | 0 |
| Anticoagulant dose at time of recurrent VTE | |||
| Full-dose | 2 (3) | 0 | 0 |
| Modified-dose | 0 | 0 | 0 |
| None | 2 (3) | 0 | 1 (8) |
| Anticoagulant at time of recurrent VTE | |||
| LMWH | 1 (1) | 0 | 0 |
| Unfractionated heparin | 1 (1) | 0 | 0 |
| Direct oral anticoagulant | 0 | 0 | 0 |
| VTE characteristics . | Full-dose (n = 75) . | Modified-dose (n = 33) . | None (n = 13) . |
|---|---|---|---|
| Total recurrent VTE events | 4 (5) | 0 | 1 (8) |
| Recurrent VTE event | |||
| Distal lower extremity DVT | 1 (1) | 0 | 0 |
| Proximal lower extremity DVT | 2 (3) | 0 | 0 |
| Upper extremity DVT | 0 | 0 | 1 (8) |
| Pulmonary embolism | 1 (1) | 0 | 0 |
| Anticoagulant dose at time of recurrent VTE | |||
| Full-dose | 2 (3) | 0 | 0 |
| Modified-dose | 0 | 0 | 0 |
| None | 2 (3) | 0 | 1 (8) |
| Anticoagulant at time of recurrent VTE | |||
| LMWH | 1 (1) | 0 | 0 |
| Unfractionated heparin | 1 (1) | 0 | 0 |
| Direct oral anticoagulant | 0 | 0 | 0 |